Skip to main content

Alkermes plc 8-K, filed Nov 12, 2026

Alkermes plc. (ALKS)

8-K 2026-11-12 For: 2026-11-06
View Original
Added on November 12, 2026

About this 8-K

Alkermes plc filed this 8-K on November 12, 2026, reporting on events of November 6, 2026.

Alkermes plc settled Teva’s LYBALVI patent litigation, granting Teva a non-exclusive, royalty-free U.S. license beginning November 12, 2039, or May 12, 2040 if pediatric exclusivity is obtained. The parties filed a Stipulation of Dismissal with Prejudice on November 9, 2026. AI summary

Items reported

  • Item 1.01: Entered into a material agreement